Nothing Special   »   [go: up one dir, main page]

MX2011007567A - Metodos para la inhibicion de la neurodegeneracion. - Google Patents

Metodos para la inhibicion de la neurodegeneracion.

Info

Publication number
MX2011007567A
MX2011007567A MX2011007567A MX2011007567A MX2011007567A MX 2011007567 A MX2011007567 A MX 2011007567A MX 2011007567 A MX2011007567 A MX 2011007567A MX 2011007567 A MX2011007567 A MX 2011007567A MX 2011007567 A MX2011007567 A MX 2011007567A
Authority
MX
Mexico
Prior art keywords
neurodegeneration
compounds
useful
app
shedding
Prior art date
Application number
MX2011007567A
Other languages
English (en)
Inventor
Marc Tessier-Lavigne
Anatoly Nikolaev
Julie Pinkston-Gosse
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2011007567A publication Critical patent/MX2011007567A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Psychology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se presentan métodos para la detección de compuestos que inhiben la neurodegeneración. El desprendimiento de APP puede ser un marcador útil para la neurodegeneración, y los compuestos que inhiben el desprendimiento de APP son útiles como inhibidores de la neurodegeneración. Dichos compuestos pueden ser útiles en el tratamiento y la prevención de diversos trastornos y enfermedades neurológicos, y del daño neuronal, y pueden aumentar el crecimiento, la regeneración o la supervivencia de tejido o células neuronales de mamíferos.
MX2011007567A 2009-02-18 2010-02-17 Metodos para la inhibicion de la neurodegeneracion. MX2011007567A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15354009P 2009-02-18 2009-02-18
PCT/US2010/024458 WO2010096470A2 (en) 2009-02-18 2010-02-17 Method for inhibiting neurodegeneration

Publications (1)

Publication Number Publication Date
MX2011007567A true MX2011007567A (es) 2011-09-28

Family

ID=42634431

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011007567A MX2011007567A (es) 2009-02-18 2010-02-17 Metodos para la inhibicion de la neurodegeneracion.

Country Status (13)

Country Link
US (1) US20120076785A1 (es)
EP (1) EP2399135A4 (es)
JP (1) JP2012518042A (es)
KR (1) KR20120011841A (es)
CN (1) CN102326083A (es)
AR (1) AR078216A1 (es)
AU (1) AU2010216107A1 (es)
BR (1) BRPI1005403A2 (es)
CA (1) CA2752171A1 (es)
IL (1) IL214647A0 (es)
MX (1) MX2011007567A (es)
TW (1) TW201034684A (es)
WO (1) WO2010096470A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2744043A1 (en) 2008-11-25 2010-06-03 Biogen Idec Ma Inc. Use of dr6 and p75 antagonists to promote survival of cells of the nervous system
RU2012124093A (ru) * 2009-11-12 2013-12-20 Дженентек, Инк. Способ увеличения плотности дендритных шипиков
US9238796B2 (en) 2010-06-04 2016-01-19 Toagosei Co. Ltd. Cell growth-promoting peptide and use thereof
US9320793B2 (en) * 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
JP6066222B2 (ja) 2012-05-28 2017-01-25 東亞合成株式会社 抗菌ペプチド及びその利用
WO2014061749A1 (ja) * 2012-10-18 2014-04-24 東亞合成株式会社 ２型ｔｎｆ受容体の発現を抑制する合成ペプチド及びその利用
WO2014159247A1 (en) 2013-03-14 2014-10-02 University Of Florida Research Foundation, Inc. Di-amino acid repeat-containing proteins associated with als
JP6600694B2 (ja) * 2015-03-16 2019-10-30 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 上位及び下位運動ニューロン機能並びに知覚の減衰を示す非ヒト動物
EP3273982B1 (en) * 2015-03-26 2020-11-18 Suzhou Auzone Biological Technology Co., Ltd Method of diagnosis or treatment of neurological disorders with p75ecd and/or p75
US10509045B2 (en) 2015-05-29 2019-12-17 University Of Florida Research Foundation, Incorporated Methods for diagnosing Huntington's disease
US10940161B2 (en) 2016-04-04 2021-03-09 University Of Florida Research Foundation, Incorporated Manipulation of EIF3 to modulate repeat associated non-ATG (RAN) translation
WO2018195110A1 (en) 2017-04-17 2018-10-25 University Of Florida Research Foundation, Incorporated Regolation of ran translation by pkr and eif2a-p pathways
JP7350337B2 (ja) 2017-09-26 2023-09-26 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． 神経障害の処置においてｒａｎタンパク質レベルを低下させるためのメトホルミンおよびそのアナログの使用
CN114958760B (zh) * 2021-02-23 2024-04-26 南京启真基因工程有限公司 一种构建阿尔兹海默症模型猪的基因编辑技术及其应用
WO2024087429A1 (zh) * 2023-02-28 2024-05-02 湖南乾康科技有限公司 用于检测蛋白生物标志物组的抗体在制备诊断ad、mci和其它类型老年痴呆的试剂盒中的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2086165A1 (en) * 1992-04-09 1993-10-10 Paul P. Tamburini Diagnostic assay for alzheimer's disease based on the proteolysis of alzheimer's precursor protein
AU719038B2 (en) * 1996-03-29 2000-05-04 Trustees Of Boston University Methods for diagnosing and treating Alzheimer's disease
FI991197A0 (fi) * 1999-05-27 1999-05-27 Mart Saarma Neurotrooppiset tekijät lantionalueen ääreishermoston toimintahäiriön hoitamisessa
AU2002255881A1 (en) * 2001-03-23 2002-10-08 University Of Utah Research Foundation Method of screening for agents that regulate the shedding of membrane bound proteins and methods of use
WO2003040183A2 (en) * 2001-11-09 2003-05-15 The Genetics Company, Inc Compounds for the diagnosis/prevention/treatment of alzheimer's disease
EP1455825A4 (en) * 2001-12-17 2006-05-31 Lilly Co Eli TREATMENT OF B-CELL-MEDIATED DISEASES BY MODULATION OF THE DR6 ACTIVITY
US20040191291A1 (en) * 2003-03-28 2004-09-30 Masaya Tohyama Composition and method for nerve regeneration
CN1849132A (zh) * 2003-09-10 2006-10-18 伦敦大学国王学院 调节神经元生长的化合物以及它们的用途
WO2005044293A2 (en) * 2003-11-07 2005-05-19 Lay Line Genomics S.P.A. Compositions able to prevent neurodegenerative processes and methods of assaying the same
US7943755B2 (en) * 2004-10-22 2011-05-17 Neuregenix Limited Neuron regeneration
CN101107268B (zh) * 2005-01-24 2012-06-27 剑桥抗体技术有限公司 针对ngf的特异性结合成员
CN101273060A (zh) * 2005-06-24 2008-09-24 美国政府（由卫生和人类服务部、国立卫生研究院的部长所代表） 通过靶向肿瘤坏死因子受体的前配体装配域(plad)来缓解炎性关节炎
US20100203044A1 (en) * 2006-12-22 2010-08-12 Anatoly Nikolaev Dr6 antagonists and uses thereof in treating neurological disorders
CA2744043A1 (en) * 2008-11-25 2010-06-03 Biogen Idec Ma Inc. Use of dr6 and p75 antagonists to promote survival of cells of the nervous system

Also Published As

Publication number Publication date
AU2010216107A1 (en) 2011-08-18
KR20120011841A (ko) 2012-02-08
JP2012518042A (ja) 2012-08-09
WO2010096470A4 (en) 2011-04-14
WO2010096470A3 (en) 2010-12-16
CA2752171A1 (en) 2010-08-26
CN102326083A (zh) 2012-01-18
WO2010096470A2 (en) 2010-08-26
EP2399135A2 (en) 2011-12-28
AR078216A1 (es) 2011-10-26
IL214647A0 (en) 2011-09-27
EP2399135A4 (en) 2012-10-17
US20120076785A1 (en) 2012-03-29
TW201034684A (en) 2010-10-01
BRPI1005403A2 (pt) 2016-10-04

Similar Documents

Publication Publication Date Title
MX2011007567A (es) Metodos para la inhibicion de la neurodegeneracion.
HK1247821A1 (zh) 用於預防或治療眼科病症的方法和組合物
HK1126121A1 (en) Method of treating abnormal cell growth
IL211857A0 (en) Method and system for neurological treatment
EP2649177A4 (en) AGENTS AND METHODS FOR INHIBITING GROWTH OF HUMAN PLURIPOTENT STEM CELLS
WO2009152463A3 (en) Method for screening for compounds that inhibit neurodegeneration
EP2249914A4 (en) IMPLANT EQUIPPED FOR NERVE LOCATION AND METHOD OF USE
PH12012500278A1 (en) Substituted xanthine derivatives
MX2009005725A (es) Metodos y composiciones para tratamiento y monitoreo de tratamiento de trastornos asociados con il-13.
ZA201006293B (en) Composition and method for seed treatment use
HK1168005A1 (en) Methods for preventing and or treating degenerative disorders of the central nervous system
WO2009114703A3 (en) Combination therapy for the treatment of cancer
IL206899A (en) A system for treating damaged brain tissue
EP2341936A4 (en) METHOD FOR TREATING OR PREVENTING IL-1ß-CONTAINED ILLNESSES
MX337849B (es) Composiciones y metodos para inhibicion de la via jak.
IN2012DN01642A (es)
WO2011047091A9 (en) Methods for treating traumatic brain injury
SG10201405392RA (en) Method of treatment of neurodegenerative or neuro-muscular degenerative diseases andtherapeutic agent to treat the same
EP2461862A4 (en) SYSTEM AND METHOD FOR STIMULATION OF POSTERIOR TIBIAL NERVE AND / OR OTHER NERVE
MD154Z (ro) Procedeu de tratare a seminţelor de triticale cu viabilitate redusă
SG195127A1 (en) Methods of treating or preventing neurological diseases
ZA200804777B (en) Method of treating abnormal cell growth
AU2016204146A1 (en) Methods of Increasing Neuronal Differentiation Using Antibodies to Lysophoshatidic Acid
MX346339B (es) (-)-huperzina a procesos y composiciones relacionadas y métodos de tratamiento.
WO2012068332A9 (en) Methods for treating early stage or mild neurological disorders